Intuitive Surgical, Inc.(ISRG)
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Latest News & Analysis
Intuitive Surgical: da Vinci Growth and Robotics Trends
Intuitive Surgical (ISRG) drives robust da Vinci system growth amid healthcare robotics innovations and evolving regulatory dynamics.
Intuitive Surgical: Navigating Market Trends & da Vinci Impact
A comprehensive analysis of Intuitive Surgical’s market trends, da Vinci system impact, and strategic initiatives in healthcare robotics.
Intuitive Surgical’s Da Vinci 5 Launch: Market Impact and Growth
Intuitive Surgical’s da Vinci 5 launch drives market impact and robust growth. Strong Q4 earnings and system adoption underscore future prospects.
Intuitive Surgical: Market Trends, da Vinci Innovation, and Competitive Landscape
A comprehensive intraday update on Intuitive Surgical (ISRG), highlighting market trends, da Vinci innovation, and competitive dynamics as of February 20, 2025.
Intuitive Surgical: Revolutionizing Healthcare with Robotic Surgery
ISRG dominates the robotic surgery market with innovative technology and global expansion.
Intuitive Surgical: Market Trends, da Vinci System Impact, and Analysis
Analysis of Intuitive Surgical's market trends, da Vinci system impact, and potential stock split. Key insights for investors and industry stakeholders.
Intuitive Surgical (ISRG): Innovations, Market Dynamics, and Growth
Intuitive Surgical (ISRG) navigates growth with strategic moves, innovation, and market dynamics, while facing competition and regulatory hurdles.
Intuitive Surgical: Navigating Growth and Innovation in Robotic Surgery
Intuitive Surgical (ISRG) navigates robotic surgery growth with da Vinci advancements, competition, and strategic European expansion. A stock split is anticipated. ISRG's PE Ratio is 89.63.
Intuitive Surgical (ISRG): Da Vinci 5 Impact, Competition, and AI Trends
Analysis of Intuitive Surgical's da Vinci 5, competitive landscape, AI integration, and global expansion strategies. ISRG stock is nearing its 52-week high.
Intuitive Surgical (ISRG): Da Vinci 5, Global Expansion, and Market Analysis
Intuitive Surgical (ISRG) navigates market dynamics with Da Vinci 5, global expansion, and analyst ratings influencing stock. A potential stock split could increase investor accessibility.
Intuitive Surgical (ISRG): Growth, Competition, and the Future
An in-depth analysis of Intuitive Surgical (ISRG), covering the da Vinci 5's impact, competition, financial performance, and growth opportunities in robotic surgery.
Intuitive Surgical (ISRG): da Vinci 5, Market Impact, and Growth
Analysis of Intuitive Surgical (ISRG): da Vinci 5 impact, market trends, competitive landscape, and financial performance amidst Nasdaq volatility.
Intuitive Surgical (ISRG): da Vinci 5 Recall and Growth Analysis
Intuitive Surgical (ISRG) faces challenges due to the da Vinci 5 recall, but its long-term growth prospects remain strong. R&D and market leadership are key.
Intuitive Surgical (ISRG): Da Vinci 5 Recall, AI, and Market Outlook
Analysis of Intuitive Surgical (ISRG): Da Vinci 5 recall, AI integration, competitive landscape, revenue growth, and valuation for investors.
Intuitive Surgical (ISRG): Navigating the Surgical Robotics Landscape After Da Vinci 5 Recall
Analysis of Intuitive Surgical's (ISRG) challenges and opportunities following the Da Vinci 5 recall, focusing on market dynamics, financial health, and strategic outlook.
Intuitive Surgical (ISRG): Da Vinci 5, Market Impact, and Future Growth
An in-depth analysis of Intuitive Surgical (ISRG), exploring the impact of Da Vinci 5's force feedback technology, hospital capital expenditure correlation, and the company's strategic response to tariffs.
Intuitive Surgical (ISRG) Navigates CEO Transition and FDA Approvals
Intuitive Surgical navigates a pivotal year with CEO transition, new FDA approvals, and robust financial growth amidst increasing competition and high market expectations.
Intuitive Surgical (ISRG): Q1 2025 Performance & Strategic Shifts
Intuitive Surgical's Q1 2025 revenue surged +14% to $1.89B amid CEO transition & new FDA clearances. Tariffs pressure margins, but growth remains robust.
Intuitive Surgical ([ISRG](/dashboard/companies/ISRG)): Market Dynamics & Strategic Growth
Explore Intuitive Surgical's latest financials, strategic innovations, market trends, and analyst insights shaping its future.
ISRG Procedure Growth vs. Margin Headwinds: Analyzing Intuitive Surgical
Analyze ISRG's robust procedure growth, rising costs, and margin pressures. Discover how Intuitive Surgical's innovation and pricing strategy impact its valuation and future profitability.
Intuitive Surgical (ISRG) Q4 2024 Earnings and Strategic Analysis: Growth Amidst Market Shifts
Intuitive Surgical reports robust 2024 revenue growth and strategic investments amid evolving surgical robotics market dynamics, with key financial and competitive insights.
Intuitive Surgical (ISRG) Market Update: da Vinci 5 Launch and Financial Outlook
Intuitive Surgical's da Vinci 5 launch in Europe redefines robotic surgery amid strong financials and competitive pressures.
Intuitive Surgical (ISRG) Advances Market Leadership with da Vinci 5 European Launch and Strong Financials
Intuitive Surgical's da Vinci 5 system gains CE Mark for Europe, reinforcing market dominance amid competition. Robust financials and innovation underpin growth.
Intuitive Surgical (ISRG) Latest Analysis: Da Vinci 5 European Launch, Utilization Growth & Competitive Position
Explore Intuitive Surgical's recent da Vinci 5 CE approval in Europe, utilization growth trends, financial performance, and competitive dynamics in robotic surgery.
Intuitive Surgical (ISRG) Q2 2025 Update: Navigating Growth with da Vinci 5 and Market Dynamics
Explore Intuitive Surgical's latest growth trends, financial performance, and strategic market positioning amid da Vinci 5 launch and competitive pressures.
Intuitive Surgical, Inc. Latest Market Update: Strong Growth and Strategic Momentum
Intuitive Surgical shows robust revenue growth, expanding operating margins, and strategic investments fueling future innovation in robotic surgery.
Intuitive Surgical (ISRG) Q2 2025 Update: Da Vinci 5 Rollout, FDA Approvals, and Navigating CapEx Headwinds
Explore Intuitive Surgical's latest growth via da Vinci 5 system rollout, Vessel Sealer Curved FDA approval, and strategies addressing hospital CapEx constraints.
Intuitive Surgical, Inc. (ISRG) Latest Financial and Market Update: Earnings Growth and Strategic Positioning
Intuitive Surgical (ISRG) reports strong revenue and net income growth in 2024, maintaining leadership in robotic surgical systems amid rising market demand.
Intuitive Surgical (ISRG) Q2 2025 Analysis: Navigating Growth and Margin Pressures Amid Innovation and Competition
Explore Intuitive Surgical's latest Q2 2025 developments, balancing strong procedure growth with margin compression from tariffs and rising costs amid competitive pressures.
Intuitive Surgical (ISRG) Q2 2025 Update: Navigating Margin Pressures Amid Robust Procedure Growth
Intuitive Surgical reports strong Q2 2025 procedure growth with margin pressures from new platforms and tariffs. Explore ISRG's margin recovery strategy and financial outlook.
Intuitive Surgical Q2 2025 Analysis: Margin Dynamics and Strategic Growth | Monexa AI
Explore Intuitive Surgical's Q2 2025 margin pressures, procedural growth, and strategic investments shaping its competitive edge and financial trajectory.
Intuitive Surgical (ISRG): Growth, Cash Flow and the Cost of Scale
Intuitive posted **FY2024 revenue of $8.35B (+17.28%)** and **FCF of $1.30B (+73.46%)** even as CAPEX stepped up to **$1.11B**, testing cash cushions and strategy execution.
Intuitive Surgical (ISRG): Q2 Beat, da Vinci 5 CE Mark and the $165M Tariff Test
ISRG beat Q2 EPS by +13.47% and won CE Mark for da Vinci 5 as management guides for heavy 2025 investment; tariffs and valuation create a delicate trade‑off.
Intuitive Surgical: FDA Win, CEO Shift, and Strong Financials
Intuitive Surgical gains FDA clearance for da Vinci SP in transanal procedures, promotes Dave Rosa to CEO, and reports strong financial growth, navigating a dynamic robotic surgery market.
Intuitive Surgical (ISRG): Revenue Rebound, Heavy CapEx and International Headwinds Reshape 2026 Stakes
Intuitive reported **FY2024 revenue $8.35B (+17.27%)** and **net income $2.32B (+28.89%)**, but rising capex, cash draw and tariff/regulatory risks make 2026 a test of execution.
Intuitive Surgical (ISRG): Tariffs Cut Into Margins Even as Da Vinci and Ion Drive Growth
Intuitive reports FY2024 revenue of **$8.35B** while flagging a **~100 bps** tariff hit to gross margin in 2025; the stock trades at **$449.98 (-3.76%)** amid a leadership change.
Intuitive Surgical Expands Platform Reach as Stock Tests 52-Week Lows Ahead of Earnings
Platform diversification through SP colorectal approval and Ion AI integration positions ISRG for Q3 catalyst despite valuation compression.